Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium

American Heart Journal

Volumn 165, Issue 4, 2013, Pages 477-488

  Sager, Philip ^a   Heilbraun, Jeffrey ^b   Turner, J Rick ^c   Gintant, Gary ^d   Geiger, Mary J ^e   Kowey, Peter R ^f,g   Mansoor, George A ^h   Mendzelevski, Boaz ⁱ   Michelson, Eric L ^j   Stockbridge, Norman ^k   Weber, Michael A ^l   White, William B ^m  

^a Sager Expert Consulting   (United States)

^b CoreLab Partners ^*  (United States)

^c IQVIA   (United States)

^d ABBVIE INC   (United States)

^e Relypsa   (United States)

^f LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ AstraZeneca LP ^*  (United Kingdom)

^j ASTRAZENECA   (United Kingdom)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l SUNY Downstate Medical Center   (United States)

^m UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMPHETAMINE; ANALGESIC AGENT; ANGIOGENESIS INHIBITOR; ATOMOXETINE; CORTICOSTEROID; CYCLOSPORIN; DEXAMPHETAMINE; DIPIVEFRINE; ERYTHROPOIETIN; ESTROGEN; GESTAGEN; IBUPROFEN; METHYLPHENIDATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; ROFECOXIB; TACROLIMUS;

ANALGESIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; HEART FAILURE; HEART INFARCTION; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; MORTALITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 84875436232     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.01.002     Document Type: Review

References (53)

1. J. Finkle, D. Bloomfield, and K. Uhl New precompetitive paradigms: focus on cardiac safety Am Heart J 157 5 2009 825 826
2. W.J. Elliott Drug interactions and drugs that affect blood pressure J Clin Hypertens (Greenwich) 8 10 2006 731 737
3. R.P. Blankfield Blood pressure, fluid retention and the cardiovascular risk of drugs Future Cardiol 8 4 2012 489 493
4. E. Grossman, and F.H. Messerli Drug-induced hypertension: an unappreciated cause of secondary hypertension Am J Med 125 1 2012 14 22
5. E. O'Brien, and J.R. Turner Assessing blood pressure responses to noncardiovscular drugs: the beneficial role of ambulatory blood pressure monitoring J Clin Hypertens (Greenwich) 15 1 2013 55 62
6. W.B. White Cardiovascular effects of the cyclooxygenase inhibitors Hypertension 49 3 2007 408 418
7. J.J. Mourad, and B.I. Levy Mechanisms of antiangiogenic-induced arterial hypertension Curr Hypertens Rep 13 4 2011 289 293
8. S.C. Textor, S.J. Taler, and V.J. Canzanello Posttransplantation hypertension related to calcineurin inhibitors Liver Transpl 6 5 2000 521 530
9. E.J. Hoorn, S.B. Walsh, and J.A. McCormick Pathogenesis of calcineurin inhibitor-induced hypertension J Nephrol 25 3 2012 269 275
10. J. Stamler, R. Stamler, and J.D. Neaton Blood pressure, systolic and diastolic, and cardiovascular risks. US population data Arch Intern Med 153 5 1993 598 615
11. Prospective Studies Collaboration S. Lewington, G. Whitlock, and R. Clarke Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 9602 2007 1829 1839
12. VA Cooperative Research Group Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg JAMA 213 1970 1143 1152
13. Medical Research Council Working Party MRC trial of treatment of mild hypertension: principal results Br Med J (Clin Res Ed) 291 1985 97 104
14. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA 265 1991 3255 3264
15. N.S. Beckett, R. Peters, A.E. Fletcher HYVET Study Group Treatment of hypertension in patients 80 years of age or older N Engl J Med 358 2008 1887 1898
16. Prospective Studies Collaboration G. Whitlock, S. Lewington, and P. Sherliker Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies Lancet 373 9669 2009 1083 1096
17. P.K. Whelton, J. He, and L.J. Appel Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program JAMA 288 2002 1882 1888
18. C. Bombardier, L. Laine, A. Reicin VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 21 2000 1520 1528
19. W.B. White, C.R. West, and J.S. Borer Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials Am J Cardiol 99 1 2007 91 98
20. R.S. Bresalier, R.S. Sandler, H. Quan Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 11 2005 1092 1102
21. C. Rosendorff, H.R. Black, and C.P. Cannon AHA scientific statement. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Councils for High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 115 2007 2761 2788
22. S.S. Franklin, V.A. Lopez, and N.D. Wong Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study Circulation 119 2 2009 243 250
23. W.C. Cushman, G.W. Evans, and R.P. Byington Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
24. P.M. Rothwell, S.C. Howard, and E. Dolan Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension Lancet 375 2010 895 905
25. R. Schutte, L. Thijs, and Y.P. Liu Within-subject blood pressure level - not variability - predicts fatal and nonfatal outcomes in a general population Hypertension 60 2012 1138 1147
26. G. Mancia, R. Facchetti, and G. Parati Visit to visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis Circulation 126 2012 569 578
27. T.W. Hansen, M. Kikuya, and L. Thijs Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals J Hypertens 25 2007 1554 1564
28. P. Verdecchia, F. Angeli, and C. Cavallini Ambulatory blood pressure for cardiovascular risk stratification Circulation 115 2007 2091 2093
29. J. Boggia, Y. Li, and T.W. Hansen Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study Lancet 6 370 2007 1219 1229
30. J.W. Graves, B.R. Grossardt, and R.E. Gullerud The trained observer better predicts daytime ABPM diastolic blood pressure in hypertensive patients than does an automated device Blood Press Monit 11 2006 53 58
31. W.B. White, M.A. Weber, and D. Sica Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension Hypertension 57 2011 413 420
32. W.B. White, T. Giles, and G.L. Bakris Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting Am Heart J 151 2006 176 184
33. J.R. Sowers, W.B. White, and B. Pitt Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and non-steroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus Arch Intern Med 165 2005 161 168
34. L. Marks, S. Borland, and K. Philp The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds Toxicol Appl Pharmacol 263 2 2012 171 1183
35. S. Authier, J.F. Tanguay, and S. Fournier Conscious and anesthetized non-human primate safety pharmacology models: hemodynamic sensitivity comparison J Pharmacol Toxicol Methods 58 2 2008 94 98
36. ICH Guideline S7A. Safety Pharmacology Studies for Human Pharmaceuticals http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S7A/ Step4/S7A-Guideline.pdf 2000 (Accessed 22nd October 2012)
37. G. Ward, P. Milliken, and B. Patel Comparison of non-invasive and implanted telemetric measurement of blood pressure and electrocardiogram in conscious beagle dogs J Pharmacol Toxicol Methods 66 2 2012 106 113
38. ICH guideline S6(R1). Preclinical safety evaluation of biotechnology-derived pharmaceuticals http://www.ich.org/fileadmin/Public-Web- Site/ICH-Products/Guidelines/Safety/S6-R1/Step4/S6-R1-Guideline.pdf 2011 (Accessed 22nd October 2012)
39. A. Sivarajah, S. Collins, and M.R. Sutton Cardiovascular safety assessments in the conscious telemetered dog: utilization of super-intervals to enhance statistical power J Pharmacol Toxicol Methods 62 1 2010 12 19
40. D.J. Leishman, T.W. Beck, and N. Dybdal Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society J Pharmacol Toxicol Methods 65 3 2012 93 101
41. L. Ewart, D. Gallagher, and T. Hammond The ABPI-Animal Model Framework: concordance of dog cardiovascular telemetry parameters to single ascending dose trials in man. Abstract presented at the 2012 Annual Meeting of the Society of Toxicology Toxicologist 126 1 2012 2704
42. A.A. Bhide, G.A. Digesu, and R. Fernando Use of mirabegron in treating overactive bladder Int Urogynecol J. 23 2012 1345 1348
43. G. Parati, G.S. Stergiou, R. Asmar ESH Working Group on Blood Pressure Monitoring European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring J Hypertens 26 2008 1505 1526
44. P. Campbell, and W.B. White Home monitoring of the blood pressure H.R. Black, W.J. Elliott, Hypertension: Companion to Braunwald's Cardiovascular Medicine 2012 WB Saunders
45. A.V. Chobanian, G.L. Bakris, and H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
46. T.G. Pickering, J.E. Hall, and L.J. Appel Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Sub-committee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research Hypertension 45 2005 142 161
47. G. Parati, G.S. Sterigou, R. Asmar ESH Working Group on Blood Pressure Monitoring European Society of Hypertension practice guidelines for home blood pressure monitoring J Hum Hypertens 24 2010 779 785
48. A.M. Ward, O. Takahashi, and R. Stevens Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies J Hypertens 30 3 2012 449 456
49. W.B. White, P. Salzman, S.R. Schwid Parkinson's Rasagiline: Efficacy and Safety in the Treatment of Parkinson Study Group Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease Hypertension 52 2008 587 593
50. J. Conway, J. Johnston, and A. Coats The use of ambulatory blood pressure monitoring to improve the accuracy and reduce the numbers of subjects in clinical trials of antihypertensive agents J Hypertens 6 1988 111 116
51. E. O'Brien, and K. O'Malley Evaluation of blood pressure measuring devices with special reference to ambulatory systems J Hypertens Suppl 8 7 1990 S133 S139
52. W.B. White, A.S. Berson, and C. Robbins National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers Hypertension 21 4 1993 504 509
53. T.G. Pickering, and W.B. White ASH position paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring J Clin Hypertens (Greenwich) 10 2008 850 855